Sana Biotechnology (NASDAQ:SANA) Cut to “Hold” at Zacks Research

Zacks Research lowered shares of Sana Biotechnology (NASDAQ:SANA) from a strong-buy rating to a hold rating in a report issued on Tuesday,Zacks.com reports.

SANA has been the topic of a number of other reports. Bank of America boosted their target price on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. HC Wainwright dropped their target price on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday. Wedbush boosted their price target on Sana Biotechnology from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Wall Street Zen downgraded shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sana Biotechnology in a report on Monday, December 29th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Sana Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.83.

Sana Biotechnology Trading Down 10.7%

Shares of NASDAQ SANA opened at $3.41 on Tuesday. The stock has a fifty day moving average price of $4.27 and a 200 day moving average price of $4.14. Sana Biotechnology has a 12-month low of $1.26 and a 12-month high of $6.55. The company has a market cap of $910.03 million, a P/E ratio of -3.52 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.03). On average, sell-side analysts forecast that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

A number of hedge funds have recently made changes to their positions in SANA. TD Waterhouse Canada Inc. acquired a new stake in shares of Sana Biotechnology during the 3rd quarter valued at $37,000. LRI Investments LLC acquired a new stake in shares of Sana Biotechnology during the 4th quarter valued at about $41,000. Jacobi Capital Management LLC bought a new stake in shares of Sana Biotechnology in the 4th quarter valued at approximately $41,000. Mercer Global Advisors Inc. ADV acquired a new position in Sana Biotechnology in the third quarter worth approximately $36,000. Finally, Foguth Wealth Management LLC. bought a new position in Sana Biotechnology during the fourth quarter valued at approximately $44,000. 88.23% of the stock is owned by hedge funds and other institutional investors.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.